Chapter 27: Assessment and Management of Patients with Hypertension

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement, not replace the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Okay, let's unpack this.

Welcome to the deep dive where we take complex clinical information and distill it down to what you absolutely need to know.

Today we are tackling a giant,

the assessment and management of hypertension.

This isn't just common, it is essential foundational knowledge for anyone pursuing patient care.

It truly is.

Hypertension, often called the silent killer, is not just a frequent diagnosis.

It's, well, it's the most common chronic disease globally.

Wow.

And it holds the unwelcome title of the single leading risk factor for premature death and disability worldwide.

When we talk about chronic disease management, this is really the cornerstone.

So for you, the learner, mastering this material is pretty non -negotiable.

Our mission today is to walk through the clinical focus of this entire chapter, step by step.

We're covering everything from the latest classifications and the complex multi -system pathophysiology all the way to the detailed nursing process and of course, crisis management.

The goal is to make sure you walk away knowing exactly how to apply this material in practice.

And understanding the stakes is paramount, isn't it?

It is.

The source material is so clear on this.

The data shows that even a relatively small increase, we're talking each 20 millimeter Hg increase in systolic blood pressure.

SBP, yeah.

Or a 10 millimeter Hg increase in diastolic, that alone doubles the risk of death from stroke or heart disease.

Doubles it, that's incredible.

It's staggering.

But the flip side is that the potential for massive risk reduction, especially through proactive lifestyle changes, is just huge.

Okay, before we jump into the classifications, let's nail down some core vocabulary we'll be using throughout this deep dive.

These definitions really structure our thinking.

Good idea.

So we'll be primarily dealing with two main origins of hypertension.

First, there's primary hypertension.

Also called essential hypertension.

Exactly.

And this is high blood pressure with no identifiable cause.

This accounts for the vast majority of cases, about 90 to 95%.

So most of the time, we don't have a single why.

That's right.

Then you have secondary hypertension.

This is high blood pressure that comes from an identified treatable underlying cause.

Like chronic kidney disease or an endocrine disorder, maybe.

Perfect examples.

It's only about five to 10 % of cases, but it's so crucial to screen for, because you might be able to fix the root problem.

And then we have to talk about the consequences.

Right.

Target organ damage.

This term refers to the physical evidence, the pathophysiologic changes in organs like the heart, brain, kidneys, and eyes that result from that longstanding pressure.

Okay, and another specific one we need to know is isolated systolic hypertension.

This is a pattern you see a lot in older adults where the systolic number, the SBP, is high, say, greater than 140, but the diastolic, the DBP, stays deceptively low, less than 80.

Interesting.

And finally, let's define the crisis states.

Okay, so you have hypertensive emergency.

That means severe elevation with evidence of actual or probable target organ damage.

This is an immediate, often IV medication situation.

And the other side of that coin.

Hypertensive urgency.

The numbers are just as high, but there's no evidence of progressive or impending target organ damage.

We can usually manage that with oral meds and very close monitoring.

Getting those definitions right really sets the stage.

Okay, let's start with how we actually define high blood pressure, because this boundary line shifted pretty dramatically in 2017.

It really did.

For decades, the standards set by the JNC guidelines, you know, it generally placed the diagnostic bar at 140 over 90 millimeter HG or higher.

Right, that's the number everyone knew.

Exactly.

But that shift is arguably one of the most important clinical developments in recent memory.

The current guidelines from the American College of Cardiology and the American Heart Association, the ACAHA, they use significantly less permissive parameters.

What's the new line in the sand?

The definition of hypertension now starts at an average systolic pressure of 130 millimeter HG or higher, or an average diastolic of 80 millimeter HG or higher.

And that change wasn't subtle.

It reframed our entire approach to prevention.

To really grasp the impact, maybe we should walk through the classification comparison because the words themselves changed.

Absolutely.

So, staying at the bottom, normal blood pressure is defined as less than 120 systolic and less than 80 diastolic.

That baseline is still consistent.

Okay, that's straightforward.

What's next?

Next up is elevated blood pressure.

That's a systolic of 120 to 129 and a diastolic of less than 80.

And that used to be called prehypertension, right?

It was.

And lumping it into that category was, well, less urgent.

The new term elevated really emphasizes that any elevation is associated with increased cardiovascular risk.

It pushes us to intervene sooner.

Makes sense.

So, where does stage one start?

Stage one hypertension kicks in at a systolic of 130 to 139 or a diastolic of 80 to 89.

This is where we start talking about medications if the patient has other high -risk factors.

And on finally, stage two.

Stage two hypertension is defined as a systolic greater than or equal to 140 or a diastolic of 90 or higher.

This range almost always mandates immediate medication.

Okay, and the rule for diagnosis is key here.

It's not just one reading.

Absolutely not.

Classification is based on the average of two or more valid reproducible measurements taken on more than two separate occasions.

And remember, if the systolic and diastolic numbers fall into different categories.

Say 135 over 78.

Perfect example.

You always classify the patient according to the highest risk category.

So in that case, it would be stage one because of the systolic pressure.

The clinical implication of this shift is, well, it's massive.

It is.

Using the new ACA definition, the prevalence of hypertension among US adults immediately jumped from 32 % up to 46%.

So nearly half the adult population now meets the criteria.

That's staggering.

It is.

But that doesn't necessarily mean a huge spike in prescriptions.

How so?

That's the subtlety of the guidelines.

For most adults whose BP falls into that elevated or even stage one category, if their 10 -year cardiac risk is low, the primary recommendation is rigorous lifestyle changes.

So the new definition is really a call to action on diet and exercise.

Exactly.

It forces patients and clinicians to focus on those interventions before the damage becomes irreversible.

But despite this greater awareness, control rates are still concerning.

Oh, they're a major public health challenge.

The source data says a staggering 35 .3 % of adults with hypertension don't even know they have it.

And of those who do know.

About 45 .4 % are not adequately controlled to meet that goal of less than 130 over 80.

It just highlights a persistent gap in both screening and adherence.

And risk isn't uniform across the population, is it?

The demographics are critical for a nurse to understand.

Absolutely.

Let's break down those risk factors, starting with the unmodifiable ones.

Advancing age is huge.

Hypertension is most prevalent in adults 75 and older, affecting over 80 % of that age bracket.

It reflects that age -related stiffening of the arteries we'll talk about later.

And there's a significant racial disparity.

A very significant one.

African -American ethnicity has the highest prevalence globally, around 58 % for men and 56 % for women.

And they tend to develop it younger and suffer more severe target organ damage.

What about gender?

We see differences there too.

Men have a greater risk until about age 64, but after that, women have a greater risk, often linked to post -menopausal changes.

Okay, so beyond those unmodifiable risks, we have the lifestyle factors.

This is where we can make a difference.

This is where the conversation really begins.

We're talking about being overweight or obese, poor diet habits,

specifically high salt, little potassium, not enough vegetables or fiber.

What about alcohol?

Excessive alcohol intake is a big one.

That's defined as more than two drinks a day for men or one for women.

And of course, any tobacco or nicotine use, including e -cigarettes, is a massive compounding factor.

And stress.

Stress and obstructive sleep apnea are also key modifiable contributors.

Let's circle back to primary versus secondary HTN for a moment.

If 90 to 95 % of cases are primary, when should a clinician really start screening for a secondary underlying cause?

You should raise that red flag for new onset or poorly controlled hypertension, especially if it's resistant to three or more drugs.

You also have to screen if the onset is abrupt or if the patient is under 30.

And anytime you see excessive target organ damage with a new diagnosis, it's just something more aggressive might be driving the pressure.

And the common causes of secondary HTN are things we should know off the top of our heads.

Absolutely.

Chronic kidney disease is a big one.

Coercation of the aorta, endocrine disorders like Cushing's syndrome or thyroid issues,

and critically obstructive sleep apnea.

We can't forget medications either.

Never.

NSAIDs, oral contraceptives, cold remedies with pseudoephedrine, excessive alcohol, cocaine, all of these can trigger or worsen hypertension.

For that five to 10 % of patients, finding and treating that underlying cause is the key.

Now let's move to the mechanics.

This is really the foundation for understanding why hypertension happens and how our medications work.

Right, and the basic equation is pretty straightforward.

Blood pressure is simply the product of cardiac output multiplied by peripheral resistance.

So BP equals CO times PR.

Exactly, and since cardiac output is just heart rate times stroke volume, any change in rate, volume, or resistance is going to impact the overall BP.

So mechanically, hypertension is either too much volume being pumped or too much constriction in the pipes, or both.

That's a perfect way to put it.

And what's so fascinating is that primary hypertension isn't just one of those things failing.

It's complex and multifactorial.

It's an interplay of behavior, environment, genetics,

all conspiring to elevate that pressure.

So let's detail the specific physiological precedents, the how, that lead to that sustained high pressure.

Let's do it.

First up, we have increased sympathetic nervous system activity.

The fight or flight system.

Precisely.

Chronic stress, psychological factors, obesity, they can lead to this persistent SNS activation.

It causes the release of norepinephrine, which leads to a faster heart rate, stronger contractions, and widespread vasoconstriction, all of which raises peripheral resistance.

Okay, what's the second major mechanism?

That involves the kidneys and volume control.

Increased renal reabsorption of sodium, chloride, and water.

So the body's holding on to salt and water.

Right, which leads to fluid volume expansion.

This is often linked to genetic variations in how the kidneys handle sodium.

If they can't excrete it effectively, the body retains water, increasing the circulating volume, and that directly increases cardiac output.

And the third mechanism is probably the most famous, the one most targeted by medication,

the renin -angiotensin -aldosterone system.

Ah, yes, the RAAS.

We should definitely slow down and walk through this cascade.

Please.

Okay, so RAAS is a hormonal system that regulates BP and fluid balance.

When the kidneys sense low blood pressure or low flow, they release an enzyme called renin.

And renin gets the ball rolling.

It does.

Renin converts a protein from the liver, angiotensinogen, into angiotensin this first.

Which is still inactive at that point.

That's right.

Then angiotensin -converting enzyme, or ACE, which is mostly found in the lungs, converts that inactive angiotensin I into the powerful active molecule angiotensin the second.

And angiotensin the second is the real villain in this story.

It's the bad actor for sure.

It drives hypertension through two primary actions.

First, it is an extremely potent phasor constrictor.

It causes arterioles to narrow, which dramatically increases peripheral resistance.

And its second action.

It stimulates the adrenal glands to release aldosterone.

And aldosterone completes the loop by acting on the kidneys.

Exactly.

Aldosterone tells the kidneys to reabsorb more sodium and water, which further increases blood volume and cardiac output.

It's a powerful, self -perpetuating, viscous cycle of volume overload and constriction.

Okay, what's the fourth mechanism?

The fourth involves the blood vessels themselves.

Decreased vasodilation due to dysfunction of the vascular endothelium.

That's the inner lining of the vessels.

So they lose their ability to relax.

Precisely.

The endothelium normally releases things like nitric oxide to keep vessels relaxed.

When it's damaged by chronic high pressure or inflammation, that ability is lost.

And fifth, there's a metabolic link, right?

Yes, insulin resistance.

This is a major factor that potentially links hypertension to type two diabetes and obesity.

High insulin levels can actually promote sodium retention and stimulate the sympathetic nervous system.

And finally, number six.

The sixth mechanism is the activation of the immune response, which contributes to vascular inflammation, stiffness, and dysfunction.

All of these systems have complex feedback loops that are supposed to regulate pressure, but in hypertension, those loops are broken.

And we have to layer in the genealogic considerations here because aging changes this whole pathology.

Why does isolated systolic hypertension become so common in older adults?

It's a structural problem.

As we age, we get an accumulation of atherosclerotic plaque and collagen deposits, which leads to a profound stiffening of the major blood vessels, especially the aorta.

So they become less like flexible hoses and more like widget pipes.

That's a great analogy.

Because they're stiff and inelastic, they can't expand easily to accommodate the blood being ejected by the heart.

Which causes that sharp rise in the systolic pressure.

Exactly, but then the stiff vessels recoil very quickly, so the pressure drops rapidly when the heart relaxes, leading to a decreased diastolic pressure.

And that gives you that characteristic pattern.

High SBP, low DBP, isolated systolic hypertension.

And it's critical to know that even if the DBP is low,

we still have to treat it.

Oh, absolutely.

Research confirms that lowering blood pressure in older adults, even with this pattern, significantly reduces cardiovascular events and mortality.

We treat that high systolic number aggressively.

Okay, now we're transitioning from the cellular mechanisms to what the patient actually experiences.

And as we said, the majority of people are asymptomatic for years.

This is why it's such an effective silent killer.

It is.

When signs and symptoms do finally appear, it usually means that vascular damage, that target organ damage, has already begun.

So the nurse needs to be really attuned to these specific system -based manifestations.

Exactly.

So let's detail where that damage shows up.

In the eyes, we might see retinal changes on a fundoscopic exam.

What kind of changes?

Things like hemorrhages, exudates, which are little pockets of fluid or protein, arteriole or narrowing, or small infarcts called cotton wool spots.

In a severe crisis, you might even see papildema, which is swelling of the optic disc.

And for the heart.

The constant increased resistance forces the left ventricle to work harder, which leads to left ventricular hypertrophy, or LVH.

The heart muscle gets thicker.

And that increased muscle mass eventually compromises the ventricle's ability to fill and pump, which can lead to angina, a heart attack, and eventually heart failure.

And what about the kidneys?

Renal involvement is insidious.

It can manifest as microalbuminuria, or later, an increase in BUN and creatinine levels.

The patient might also report nocturia having to get up to urinate at night.

And finally, the brain.

Cerebrovascular damage can lead to a TIA or a full -blown stroke.

Most often, ischemic infarctions.

And those manifest acutely.

Yes.

Sudden dizziness, confusion, weakness, vision or speech changes, or temporary paralysis.

Any of those are huge alarm bells signaling long -term uncontrolled disease.

So the entire framework of management really relies on one thing.

Accurate blood pressure measurement.

It's everything.

This is not a simple skill.

It's a critical, meticulous nursing procedure.

And any error can lead to a misdiagnosis.

It's based on an average of at least two readings on at least two separate occasions.

That's right.

So we have to prevent measurement error at every single step.

Let's walk through that procedure checklist.

Let's start with patient prep.

What has to happen before you even put the cuff on?

First, the patient has to be in a neutral physiologic state.

They need to avoid eating, smoking, drinking caffeine, or exercising for at least 30 minutes prior, and they should empty their bladder.

If they haven't done those things, the reading will be artificially high.

Exactly.

It could lead to a false diagnosis or unnecessary treatment.

And their posture is non -negotiable.

They have to sit quietly for five minutes, back supported, feet on the ground.

Feet flat on the ground, not dangling or crossed.

And the arm has to be supported at heart level.

If the arm is unsupported, muscle tension can add 10 to 15 millimeter Hg to the reading.

And if the patient is talking, that can add 10 millimeter Hg.

The environment has to be quiet, and the patient has to be relaxed.

This level of standardization is just essential.

Okay, now let's talk about the practitioner's technique.

Cuff size is a big one.

It's a critical point.

The source material specifies the cuff's bladder width should be at least 40 % of the arm circumference, and the length should be 80 to 100 % of the circumference.

An undersized cuff gives you a high reading, and an oversized one gives you a low reading.

That's right, it's one of the most common errors.

The cuff bladder must be centered directly over the brachial artery.

And you have to palpate the systolic pressure before you auscultate.

Why is that step so important?

To detect the auscultatory gap.

This is a silence you can sometimes hear between the systolic and diastolic pressures, especially in patients with severe hypertension and stiff arteries.

So you could miss the true systolic pressure.

Easily.

If you don't palpate first, you might inflate the cuff to, say, 160, miss the true systolic pressure of 200, and mistake the return of the sound at 150 as the systolic pressure.

It's a dangerous clinical error.

The meticulous technique continues.

You have to check both arms initially.

Right, and then all future measurements should be taken from the arm with the higher reading.

And you have to take at least two readings, one to two minutes apart, and average them.

Okay, so here's where it gets really interesting.

Clinic readings are often inaccurate.

We have to move beyond just that one measurement.

This is why home blood pressure measurement, HBPM, or ambulatory blood pressure measurement, ABPM, are so important to confirm the diagnosis and check if treatment is working.

And these methods help identify those paradoxical hypertension types.

Let's start with masked hypertension.

Right, so this is when the BP is normal in the clinic, maybe 120 over 70, but outside the clinic, at home or at work, it's consistently high.

These patients still suffer the bad outcomes if they're left untreated.

And the opposite of that is white coat hypertension.

Exactly, the BP is high only in the healthcare setting, probably due to anxiety.

This runs the risk of unnecessary treatment and side effects.

Using home or ambulatory monitoring helps us avoid that.

Okay, moving to the physical exam.

The nurse needs to look for subtle signs of secondary causes or target organ damage.

Yes, you need to check peripheral pulses carefully.

Absent, weak, or delayed femoral pulses could suggest coarctation of the aorta.

You also need to listen for a renal artery brute.

Right, a swishing sound over the upper abdomen, which strongly suggests renal artery stenosis.

The cardiac exam is also crucial for evaluating for signs of that left ventricular hypertrophy we talked about.

And finally, the diagnostic lab tests complete the picture.

We use these to assess the extent of organ damage and screen for those secondary causes.

It's usually a urinalysis, blood chemistry, so sodium, potassium, creatinine, glucose, cholesterol, and a 12 -lead ECG.

So elevated BUN and creatinine would point to kidney damage.

Exactly, and the ECG can screen for signs of LVH, which you can then confirm with an echocardiogram.

All this information builds the complete clinical picture for that patient.

So the overarching goal of hypertension treatment is, well, absolutely critical.

Prevention of complications and death by maintaining the BP lower than 130 over 80.

And achieving that aggressive target really makes a difference.

It significantly lowers mortality, stroke, and overall cardiovascular disease rates.

Okay, let's talk about the pathway to that goal.

What's the timeline for follow -up after an initial screening?

If the initial BP is normal, less than 120 over 80, you just reevaluate in one year.

But if the patient has elevated BP, so that's 120 to 129 systolic and less than 80 diastolic, they need to follow up within three to six months.

And the focus there is entirely on lifestyle changes.

Right, no medication yet, typically.

But if the initial reading is consistent with stage one HTN, so 130 or higher or 80 or higher, the follow -up has to be within one month to confirm the diagnosis.

And what's the exception for immediate treatment?

That would be a patient with confirmed stage two HTN, so an average BP of 160 over 100 or higher on one occasion.

Those patients start antihypertensive medication immediately, along with lifestyle counseling.

And even for those patients on medication, the power of lifestyle changes can't be overstated.

Not at all.

The ACCHA guidelines strongly advocate for these interventions.

Let's detail the quantitative impact, because this is the data nurses need to motivate their patients.

Okay, start with weight reduction.

The goal is a BMI between 18 .5 and 24 .9.

The key teaching point is that patients can expect about a one millimeter HG systolic drop for every one kilogram of weight they lose.

So that can really add up.

Oh, it can translate to an overall SBP reduction of five to 11 millimeter HGH.

That's like a whole medication dose.

And the DHAH eating plan is equally powerful.

Right, rich in fruits, vegetables, low -fat dairy with reduced saturated fat.

For patients with hypertension, this diet alone can give you a dramatic 11 millimeter HG reduction in systolic pressure.

That's huge.

It is.

Then there's sodium and potassium balance.

The goal is less than two grams of sodium per day and 3 ,500 to 5 ,000 milligrams of potassium.

And the combination is key.

Yes, the combination of high potassium and low sodium is more effective than either one alone.

But a crucial caution,

high potassium diets are no go for patients with chronic kidney disease.

Because they can't excrete it and you risk hyperkalemia.

Exactly.

And finally, physical activity.

Regular aerobic activity for 90 to 150 minutes weekly plus resistance training.

That can yield a reduction of five to eight millimeter HG.

These are real therapeutic interventions.

Okay, let's turn to pharmacologic therapy.

The medication strategy is risk -based.

Right, any patient with stage two HTN or a stage one patient with a high 10 -year risk of a cardiac event, so 10 % or higher, is a candidate for medication.

And the first line agents are the big four.

That's right.

Thiazide or thiazide type diuretics, ACE inhibitors, ARBs and calcium channel blockers.

These are the building blocks.

Let's quickly go through the nursing considerations for each.

First, thiazide diuretics like chlorthalidone.

These decrease blood volume and cardiac output.

The key nursing note is to monitor electrolytes.

They cause loss of potassium, so you have to encourage potassium -rich foods and watch for orthostatic hypotension, especially in older adults.

Second, ACE inhibitors like lisinopril.

These block the conversion of angiotensin I to angiotensin II, lowering peripheral resistance.

They can cause hyperkalemia, so you monitor potassium.

And the famous side effect.

The persistent dry hacking cough.

And, rarely, the life -threatening angioedema.

And they are absolutely contraindicated in pregnancy.

Third, ARBs, like losartin.

They block the effects of angiotensin II at the receptor.

Similar considerations to ACE inhibitors.

Watch for hyperkalemia.

No pregnancy.

They're mainly used for patients who got that cough from an ACE inhibitor.

And fourth, calcium channel blockers, or CCBs.

We have two main types.

Right.

The dihydropyridines, like amlodipine, are strong vasodilators.

They're great for isolated systolic hypertension.

The key side effect is dose -dependent pedaledema, or swelling in the feet.

And then non -dihydropyridines, like verapamil and tiltiasm.

They reduce afterload, but also slow cardiac impulse conduction, so a crucial warning is to avoid using them with beta blockers, which can lead to severe bradycardia.

Okay, now for special populations.

What's the distinction for African American patients without heart failure or CKD?

This is a vital clinical distinction.

For this population, the guidelines recommend a thiazide diuretic, or a CCB, as the first line agent.

So ACE inhibitors and ARBs are not first line.

That's right, the rationale is linked to physiology.

African American patients often have low renin levels and are more fault sensitive, so agents targeting volume or direct vasodilation tend to be more effective.

What about patients with heart failure, with reduced ejection fraction?

There, the preferred agents are ACE inhibitors, ARBs, or specific beta blockers because they've been proven to reduce mortality, and critically, non -dihydropyridine CCBs are not recommended because they can worsen heart failure.

And for patients with chronic kidney disease?

ACE inhibitors or ARBs are preferred, regardless of race, especially if there's protein in the urine.

These drugs are reno protective.

And finally, pregnancy.

We know ACEs and ARBs are out.

Strictly forbidden.

The first line agents are methotopa, mifedipine, or labetolol because of their safety profiles.

One last point here, resistant hypertension.

What is it?

It's defined as BP that's not controlled despite taking three or more drugs, including a diuretic, or if it's only controlled by using four or more medications.

And the first step in management is checking for?

Adherence.

You have to rule out financial barriers, side effects, or a lack of understanding.

If adherence is confirmed, then you screen for a secondary cause.

Okay, here's where it gets really compelling and timely.

The COVID -19 considerations and the connection to that REAS system we just discussed.

It's a brilliant example of modern research influencing practice.

So SARS -CoV -2 uses the ACE2 receptor to get into host cells, and ACE2 normally converts angiotensin II to the protective angiotensin I to VII.

And the initial hypothesis was, well, it was concerning.

Patients on ACE inhibitors or ARBs have more of those ACE2 receptors, so the fear was they might be more susceptible to infection.

Right.

But the pathology turned out to be more complex.

Once the virus gets in, it actually down -regulates ACE2.

This leaves that potent vasoconstrictor, angiotensin II, unopposed.

Which leads to all the bad things.

Yeah.

Inflammation, thrombosis, lung injury.

Exactly.

And because patients on ACE inhibitors or ARBs already have an upregulation of ACE2 before they get infected, it might actually offer a protective advantage.

It allows for more of that good angiotensin I to VII to be produced.

Oh, it mitigates the damage.

The retrospective studies support this.

Patients with COVID -19 and hypertension who stayed on their ACEI or ARBs had lower inflammatory markers, were less critically ill, and had lower mortality rates.

So the bottom line is, keep taking the medication.

Absolutely.

No reason to stop.

Okay, let's transition to the gerontologic management caveats.

We know the target is less than 130 over 80 for most adults.

But with older patients, it requires a very careful approach.

The essential rule here is, start low and go slow.

You have to begin with a low dose and increase it very slowly, monitoring carefully for adverse effects.

Safety is the priority.

What are we monitoring for specifically?

Falls, orthostatic hypotension, and reduced renal function.

Older adults have impaired cardiovascular reflexes, so they can't compensate as quickly for changes in position or volume.

The guidelines also acknowledge some nuance here, don't they?

They do.

For older adults with multiple comorbidities, limited life expectancy, or cognitive impairment, a less aggressive BEP target may be reasonable.

Now let's put on our nurse hats and review the nursing process.

The source material says nurse -led management actually results in better control rates.

It does.

Nurses are the front line for assessment, education, and promoting adherence.

So beyond the meticulous BEP measurement, what else does the nurse need to assess?

You have to assess for other cardiovascular risk factors and signs of target organ damage.

Ask about angina, shortness of breath, vision changes, headaches, nocturia.

And you have to screen for obstructive sleep apnea.

Definitely.

Often, the patient's partner is the best source for questions about snoring or gasping at night.

And assessment goes beyond the clinical signs.

You have to look at psychosocial barriers.

Right.

Ask about financial resources, insurance, health beliefs, depressive symptoms, and social support.

Lack of control in these areas directly undermines adherence.

And there's some interesting nursing research on this.

There is.

The profile and the source material found that among African -American patients, it wasn't social support or health beliefs that correlated with adherence.

It was the presence of other comorbidities.

So participants with more health problems were more likely to take their medication.

Right.

2 .63 times more likely.

It suggests that patients who feel sick are more motivated than those who are totally asymptomatic.

And that has huge implications for nursing practice.

Massive.

It means we have to be extra vigilant and creative with education for that asymptomatic patient who feels perfectly fine because they might be at the greatest risk for non -adherence.

Okay, moving to nursing diagnosis and planning.

Based on the assessment, the standard diagnoses are often lack of knowledge and impaired ability to manage the regimen.

The goal should center on control and prevention of complications.

So our interventions focus heavily on promoting health management and adherence.

You have to relentlessly emphasize that the goal is controlling hypertension, not curing it.

This is lifelong.

When you're teaching about diet, explain that it takes two to three months for taste buds to adapt to less salt.

And rigorously avoid all tobacco and nicotine products.

Including e -cigarettes as they just amplify heart disease risk.

And what about promoting adherence?

Encourage active self -monitoring.

Daily or weekly BP checks and tracking diet gives immediate feedback and fosters a sense of control.

Encourage small, gradual changes.

Okay, and in home and transitional care,

proper technique for self -monitoring is paramount.

You have to make sure they're doing it right feet on the floor, sitting still, correct cuff size, and that their home device is accurate.

And we must provide clear, written information about medications.

A critical point here is about rebound hypertension.

Yes, that's the pathologically high blood pressure that happens when patients abruptly stop their medication.

They must be advised to maintain a continuous supply and never stop without consulting their provider.

And we have to address sensitive side effects proactively, like sexual dysfunction.

Right, let the patient know that alternatives are available so they don't just stop their medication out of embarrassment.

This leads directly into a critical quality and safety nursing alert.

Yes, antihypertensive medications can cause hypotension or orthostatic hypertension.

We must educate patients, particularly older adults, to change positions slowly to prevent falls.

They may need supportive devices like handrails or walkers.

So the final critical area is understanding hypertensive crises.

These happen when the SBP goes over 180 or the DBP goes over 120.

These often happen in patients who have been chronically poorly controlled, or very commonly, in those who have abruptly stopped their medication.

Leading to that dangerous rebound hypertension, we divide them into emergency and urgency based on the presence of organ damage.

Let's start with hypertensive emergency.

This is severe BP elevation with new or worsening evidence of target organ damage.

It's a life -threatening situation.

What are some examples of that damage?

Hypertensive encephalopathy so, severe headache, confusion, seizures,

acute ischemic stroke or an MI, heart failure with pulmonary edema, a dissecting aortic aneurysm, or acute renal failure.

So management requires immediate ICU admission.

Right.

For continuous BP monitoring and IV antihypertensives, drugs like necardipine or libidolol that are immediate and highly titratable.

And the goal for reducing BP is highly specific, depending on the underlying damage.

Yes.

For suspected aortic dissection, the goal is extremely aggressive.

Reduce the systolic to less than 120 within the first hour.

Why so aggressive?

Because the high pressure creates intense sheer stress on the aortic wall, risking a catastrophic rupture.

You have to drop the pressure fast, stop the deception from progressing.

But for other emergencies like an MI, the goal is much slower.

Right.

Reduce the SBP by no more than 25 % within the first hour.

Why the caution?

To prevent cerebral hypoperfusion.

If you drop the BP too fast in a patient whose brain is used to extremely high pressures, you can actually cause a stroke or MI.

After that initial drop, the goal is to get to 160 over 100 in the next two to six hours.

Now contrast that with a hypertensive urgency.

Okay, so this is the same severe BP elevation, but in a stable patient without evidence of impending or progressive target organ damage, the patient might just have a bad headache.

And the cause is usually non -terence.

Typically.

So management focuses on restarting or increasing oral medications over 24 to 48 hours.

But the crucial nursing step is figuring out why they weren't taking their meds finances, side effects, to prevent it from happening again.

And in both crises,

extremely close monitoring is mandatory.

Absolutely.

Vital signs every five minutes if the BP is changing rapidly.

You have to anticipate and prevent a sudden precipitous drop in pressure.

Hashtag tag outro.

So what does this all mean for you, the practicing clinician?

We've covered a massive amount of essential material today.

We really have.

We've established that new classification starting at 130 over 80, detailed the complex pathology driven by RAAS and the SNS and identified those silent killer manifestations.

Crucially, we emphasize the non -negotiable need for accurate BP measurement, getting that procedure right and the tiered treatment approach, lifestyle first, then the big four medications.

Tailored specifically to the patient's comorbidities and demographics.

And we reviewed the essential nursing framework from meticulous assessment of organ damage and psychosocial barriers, all the way to patient education focused on controlling the disease for life.

And warning against the danger of rebound hypertension.

Right.

And this raises an important question tying back to that nursing research on adherence.

Since patients who feel sick are more likely to adhere to treatment, how can we as nurses effectively convey the silent life -threatening danger of hypertension to the otherwise completely asymptomatic patient?

That's the real challenge, isn't it?

How do you motivate lifelong adherence when the only symptom is often a feeling of wellness and the treatment is a pill that might cause side effects?

That challenge of behavior modification remains the great clinical hurdle in hypertension management.

A profound thought for you to carry forward as you approach patient education.

Thank you for joining us for this crucial deep dive into hypertension assessment and management.

We hope you feel thoroughly equipped to handle this most common of chronic diseases.